Bayer raises 2026 profit outlook on strong pharmaceuticals performance
Bayer raised its 2026 profit outlook after its pharmaceuticals division delivered stronger-than-expected third-quarter sales. The German group also lowered its debt forecast, signalling improving growth momentum and a stronger financial position.
German pharmaceuticals and agriculture group Bayer on Tuesday raised its 2026 profit outlook, citing stronger-than-expected performance in its pharmaceuticals business, which delivered sales above market estimates in the third quarter, Reuters reported.The company now expects adjusted core earnings, on a currency-adjusted basis, to reach between 9.8 billion euros and 10.3 billion euros in 2026. This compares with its previous forecast of 9.6 billion euros to 10.1 billion euros.US MarketsPowered ByAs on 03 Nov 2026, 02:30 AM ISTS&P 500 Top GainersIDEXX Laboratories671.64(21.85%)Molson Coors Beverage43.23(7.75%)LKQ19.93(7.38%)Howmet Aerospace212.99(6.91%)Gainers»S&P 500 Top LosersIntel59.97(-8.80%)Oracle119.22(-8.76%)Coterra Energy32.56(-8.62%)Datadog216.10(-8.15%)Losers»Read more: Global Market Today: Asian stocks slide as US chip selloff deepensBayer's pharmaceuticals business reported third-quarter sales of 4.68 billion euros, beating analysts' expectations by 5%, according to a poll conducted by Vara Research.
